Cyramza (ramucirumab) may be a cancer drugs that interferes with the expansion and unfold of cancer cells within the body.
Cyramza is employed to treat abdomen cancer, large intestine cancer, or non-small cell carcinoma that has unfoldto alternative elements of the body. Ramucirumab could also be given alone or together with alternative cancer medicines.
Cyramza is typically given when alternative cancer medicines are tried while not success.
Submit your review
Get emergency medical help if you have signs of an allergic reaction to Cyramza: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Some side effects may occur during the injection. Tell your caregiver right away if you feel light-headed, chilled, sweaty, or have chest pain, chest tightness, back pain, trouble breathing, or numbness and tingling.
Cyramza can increase your risk of serious bleeding.
Call your doctor at once if you have:
any wound that will not heal;
headache, confusion, change in mental status, vision loss, seizure (convulsions);
severe or ongoing stomach pain, vomiting, or diarrhea;
a light-headed feeling, like you might pass out;
low white blood cell counts - fever, swollen gums, painful mouth sores, pain when swallowing, skin sores, cold or flu symptoms, cough, trouble breathing;
dangerously high blood pressure - severe headache, blurred vision, buzzing in your ears, anxiety, shortness of breath, uneven heartbeats;
kidney problems - puffy eyes, swelling in your ankles or feet, weight gain, urine that looks foamy;
signs of stomach bleeding - severe stomach pain, bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds;
symptoms of a blood clot - sudden numbness or weakness (especially on one side of the body), sudden severe headache, slurred speech, problems with vision or balance; or
heart attack symptoms - chest pain or pressure, pain spreading to your jaw or shoulder, nausea, sweating.
Common Cyramza side effects may include:
feeling weak or tired;
low white blood cell counts; or
high blood pressure.
Gastric Cancer The recommended dose of CYRAMZA either as a single agent or in combination with weekly paclitaxel is 8 mg/kg every 2 weeks administered as an intravenous infusion over 60 minutes. Continue CYRAMZA until disease progression or unacceptable toxicity. When given in combination, administer CYRAMZA prior to administration of paclitaxel. Non-Small Cell Lung Cancer The recommended dose of CYRAMZA is 10 mg/kg administered by intravenous infusion over 60 minutes on day 1 of a 21-day cycle prior to docetaxel infusion. Continue CYRAMZA until disease progression or unacceptable toxicity. Colorectal Cancer The recommended dose of CYRAMZA is 8 mg/kg every 2 weeks administered by intravenous infusion over 60 minutes prior to FOLFIRI administration. Continue CYRAMZA until disease progression or unacceptable toxicity.